{"doi":"10.1016/j.tranon.2020.100805","title":"MicroRNA200a enhances antitumor effects in combination with doxorubicin in hepatocellular carcinoma","abstract":"Hepatocellular carcinoma (HCC) is often treated with doxorubicin. MicroRNAs have been shown to have important regulatory roles in cancer and serve as a target in chemoresistance. In this study, we investigated the effects of specific microRNA-200a (miR-200a) on HCC tumor cell growth and effect of doxorubicin-mediated cytotoxicity. Our results show miR-200a is downregulated in human HCC and HCC tumor cell lines. Increasing miR-200a expression inhibited HCC growth and synergized with the antitumor effects of doxorubicin. Inhibiting endogenous miR-200a promoted tumor growth and chemotherapeutic resistance. Increasing miR-200a expression inhibited tumor metabolism (ATP production, mitochondrial respiration, glycolysis), while inhibition of endogenous miR-200a reversed these effects. MiR-200a expression also increased autophagy and synergized with doxorubicin-mediated cytotoxicity. This study identifies a novel role of miR-200a in potentiating doxorubicin-mediated therapeutic effects in HCC.","journal":"Translational Oncology","year":2020,"id":113036,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9553,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":534567,"name":"Dachen Zhou","orcid":null,"position":1,"is_corresponding":false},{"id":280837,"name":"Qiang Du","orcid":"0009-0003-7172-5682","position":2,"is_corresponding":false},{"id":379433,"name":"Peiqi Wan","orcid":"0000-0003-1951-9147","position":3,"is_corresponding":false},{"id":379431,"name":"Kun Dong","orcid":"0000-0003-3030-7962","position":4,"is_corresponding":false},{"id":534568,"name":"Hui Hou","orcid":null,"position":5,"is_corresponding":false},{"id":280838,"name":"David A. Geller","orcid":"0000-0003-0735-1068","position":6,"is_corresponding":false},{"id":379432,"name":"Xiao Cui","orcid":"0000-0002-2456-5634","position":0,"is_corresponding":true}],"reference_count":39,"raw_metadata":null,"created_at":"2026-07-18T23:13:17.845093Z","pmid":"32563177","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}